Amgen Worldwide
A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
オンラインリソース
アムジェンは、患者さんが関心のある分野について学べるよう、多数のリソースを用意しております。
疾患教育
重点領域
A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world.
アムジェンは、患者さんが関心のある分野について学べるよう、多数のリソースを用意しております。
アムジェン株式会社（以下「アムジェン」）は、鹿児島における循環器病対策の取り組みの一つとして、国立大学法人鹿児島大学（以下「鹿児島大学」）と共に急性冠症候群（ACS）再発予防のためのACSヘルスケアエコシステム形成プロジェクトを開始します。本プロジェクトでは、鹿児島大学心臓血管・高血圧内科学分野が主体となって運営する「OK-ACSレジストリー」を用いて、鹿児島県における急性心筋梗塞患者の治療および管理の状況を把握し、その課題を特定し改善のための啓発活動を推進します。
鹿児島大学 心臓血管・高血圧内科学の大石充教授は次のように述べています。「循環器領域のイノベーターとして世界100カ国以上で活動するアムジェンの皆さんと循環器病対策に取り組めることを大変嬉しく思います。循環器病の発症抑制を目指すためには、まず正確な現状把握が必要なことは言うまでもありません。鹿児島大学では、2021年から多くの県内医療従事者の皆様の協力を得て、ACS患者の二次予防としてLDL-Cなどガイドラインに準拠して管理目標値を設定した『鹿児島Style』を作り実地診療に役立てています。さらにそれを基にした鹿児島県全域におけるACSの登録研究であるOK-ACSレジストリーを立ち上げ、データベースを活用し、県内のACS患者さんの治療実態把握に努めています。レジストリーから得られる知見をもとに医療機関に対する教育啓発活動も実施します。こうした活動を通じてアムジェンの皆さんと共にACS患者さんの診療の質向上に取り組んで行きたいと思います」
厚生労働省患者調査（2017）によると、継続的に治療を受けている鹿児島県内の患者数は脳血管疾患が50,000人、急性心筋梗塞を含む虚血性心疾患が24,000人と推定されています。また厚生労働省の人口動態統計（2020）によると、循環器病のうち、心疾患、脳血管疾患、大動脈瘤および解離による死亡が、県内における死因の約4分の1を占めており、全国と比較しても死亡原因に占める循環器病の割合が高くなっています。
アムジェン株式会社メディカルアフェアーズ本部長のヘレン・リンは次のように述べています。「鹿児島大学と共にACS診療の課題に取り組むことができることをとても光栄に思います。アムジェンでは、私たちのミッションであるTo Serve Patientsを実現するために、治療薬の提供にとどまらず、全世界で医療制度の持続可能性、患者さんの治療環境の改善という観点からさまざまな組織と協力して課題解決に取り組んでいます。食事や運動療法に加え、徹底した脂質管理の重要性を、医療従事者、ACS患者さんとその家族が認識し、適切な治療を継続できる環境を整えることによって、ACSの再発を抑えられる可能性があります」
ACSなどの虚血性心疾患は心不全を引き起こす原因の一つで、全心不全患者の３割を占めます1。超高齢化社会を迎える日本において心不全患者の数は毎年増えており、2030年には130万人に達すると推計されています2。心不全になると身体機能の低下、それに伴う労働生産性の低下3、介護者の精神・身体的負担4などにつながることからも、ACS患者の再発予防対策は重要です。
健康寿命の延伸等を図るための脳卒中、心臓病その他の循環器病に係る対策に関する基本法
脳血管疾患と心疾患を合わせた循環器病は、悪性新生物（がん）に次ぐ死亡原因（23.2%）となっています5。高齢者では悪性新生物を上回り死因の1位です6。また循環器病は、介護が必要となった原因（21.2%）として最多となっています7。さらに傷病分類別診療医療費のうち、循環器病が占める割合は、約6兆円と最多です8。このような背景から循環器病対策は日本の喫緊の課題であり、「健康寿命の延伸等を図るための脳卒中、心臓病その他の循環器病に係る対策に関する基本法」が2019年12月に施行されました。現在、2020年10月に閣議決定された「循環器病対策推進基本計画（以下、基本計画）」をもとに、各都道府県での循環器病対策推進計画の策定と実行が進められています。
急性冠動脈症候群（ACS）について
急性冠症候群 （ACS：Acute Coronary Syndrome）とは、冠動脈の血管が狭くなったり、詰まったりすることにより、心筋組織に十分な血液が供給されなくなることで引き起こされる症候群のことです。急性心筋梗塞、不安定狭心症、虚血による心臓突然死が含まれます。
アムジェン株式会社について
アムジェン株式会社は、世界最大規模の独立バイオテクノロジー企業である米国アムジェン社の日本法人です。アムジェン株式会社では、循環器疾患、がん、骨疾患、炎症・免疫性疾患、神経疾患を始めとするアンメット・メディカル・ニーズが高い領域に焦点を絞り、「To serve patients – 患者さんのために、今できるすべてを」というミッションのもと、臨床開発から販売までの活動を行っています。詳細については www.amgen.co.jp をご覧になるか、https://www.facebook.com/amgenjapan
をフォローしてください。
Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of
Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking
statements, including any statements on the outcome, benefits and synergies of collaborations, or potential
collaborations, with any other company (including BeiGene, Ltd., Kyowa-Kirin Co., Ltd., or any collaboration to
manufacture therapeutic antibodies against COVID-19), the performance of Otezla® (apremilast) (including
anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Five Prime Therapeutics, Inc.
acquisition, or the Teneobio, Inc. acquisition, as well as estimates of revenues, operating margins, capital
expenditures, cash, other financial metrics, expected legal, arbitration,
political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement
activities and outcomes, effects of pandemics or other widespread health problems such as the ongoing COVID-19
pandemic on our business, and other such estimates and results. Forward-looking statements involve significant risks
and uncertainties, including those discussed below and more fully described in the Securities and Exchange
Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic
reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as
of the date of this news release and does not undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future events or otherwise.
No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints we have selected. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market.
Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.
注意事項（アムジェン株式会社）
このニュースリリースに含まれている医薬品（開発中のものを含む）に関する情報は、宣伝広告、医学的アドバイスを目的とするものではありません。
###
この件に関するお問い合わせ先
アムジェン株式会社
コーポレート・アフェアーズ
TEL 03-5293-9694
References